Exploring the Contribution of the AcrB Homolog MdtF to Drug Resistance and Dye Efflux in a Multidrug Resistant Isolate.

Sabine Schuster, Martina Vavra, Ludwig Greim, Winfried V Kern
Author Information
  1. Sabine Schuster: Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, 79106 Freiburg, Germany. ORCID
  2. Martina Vavra: Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, 79106 Freiburg, Germany.
  3. Ludwig Greim: Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, 79106 Freiburg, Germany.
  4. Winfried V Kern: Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, 79106 Freiburg, Germany.

Abstract

In , the role of RND-type drug transporters other than the major efflux pump AcrB has largely remained undeciphered (particularly in multidrug resistant pathogens), because genetic engineering in such isolates is challenging. The present study aimed to explore the capability of the AcrB homolog MdtF to contribute to the extrusion of noxious compounds and to multidrug resistance in an clinical isolate with demonstrated expression of this efflux pump. An / double-knockout was engineered, and susceptibility changes with drugs from various classes were determined in comparison to the parental strain and its and single-knockout mutants. The potential of MdtF to participate in the export of agents with different physicochemical properties was additionally assessed using accumulation and real-time efflux assays with several fluorescent dyes. The results show that there was limited impact to the multidrug resistant phenotype in the tested strain, while the RND-type transporter remarkably contributes to the efflux of all tested dyes. This should be considered when evaluating the efflux phenotype of clinical isolates via dye accumulation assays. Furthermore, the promiscuity of MdtF should be taken into account when developing new antibiotic agents.

Keywords

References

  1. Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395 [PMID: 33151290]
  2. J Bacteriol. 2001 Oct;183(20):5803-12 [PMID: 11566977]
  3. Front Microbiol. 2011 Sep 16;2:189 [PMID: 21954395]
  4. Antimicrob Agents Chemother. 2016 Mar 25;60(4):1974-83 [PMID: 26824939]
  5. Mol Microbiol. 2014 Feb;91(3):508-21 [PMID: 24330203]
  6. Antimicrob Agents Chemother. 2021 Jan 20;65(2): [PMID: 33199388]
  7. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3509-14 [PMID: 26976576]
  8. mBio. 2021 Mar 30;12(2): [PMID: 33785633]
  9. Antibiotics (Basel). 2020 Apr 01;9(4): [PMID: 32244694]
  10. Antimicrob Agents Chemother. 2001 Jan;45(1):105-16 [PMID: 11120952]
  11. EBioMedicine. 2019 Mar;41:479-487 [PMID: 30852163]
  12. J Antimicrob Chemother. 2006 Feb;57(2):344-8 [PMID: 16354746]
  13. Antimicrob Agents Chemother. 2020 Sep 21;64(10): [PMID: 32778545]
  14. Antimicrob Agents Chemother. 2010 Sep;54(9):3770-5 [PMID: 20606071]
  15. J Bacteriol. 2005 Oct;187(19):6701-7 [PMID: 16166532]
  16. PLoS One. 2011;6(6):e21196 [PMID: 21698261]
  17. Microb Drug Resist. 2010 Jun;16(2):87-9 [PMID: 20438348]
  18. Molecules. 2019 Jan 29;24(3): [PMID: 30699887]
  19. J Antimicrob Chemother. 2007 Jun;59(6):1216-22 [PMID: 17062614]
  20. J Antimicrob Chemother. 2015 Jan;70(1):81-8 [PMID: 25193085]
  21. Int J Antimicrob Agents. 2017 Sep;50(3):477-481 [PMID: 28689875]
  22. Lancet Infect Dis. 2018 Mar;18(3):318-327 [PMID: 29276051]
  23. Antimicrob Agents Chemother. 2000 Apr;44(4):814-20 [PMID: 10722475]
  24. Antimicrob Agents Chemother. 2021 Mar 18;65(4): [PMID: 33468485]
  25. Antimicrob Agents Chemother. 2014 Nov;58(11):6870-8 [PMID: 25182653]
  26. J Biol Chem. 2011 Jul 29;286(30):26576-84 [PMID: 21642439]

Grants

  1. 115525 ND4BB/Seventh Framework Programme

Word Cloud

Created with Highcharts 10.0.0effluxMdtFmultidrugRND-typepumpAcrBaccumulationresistantisolatesresistanceclinicalstrainagentsreal-timeassaysdyesphenotypetesteddyeroledrugtransportersmajorlargelyremainedundecipheredparticularlypathogensgeneticengineeringchallengingpresentstudyaimedexplorecapabilityhomologcontributeextrusionnoxiouscompoundsisolatedemonstratedexpression/double-knockoutengineeredsusceptibilitychangesdrugsvariousclassesdeterminedcomparisonparentalsingle-knockoutmutantspotentialparticipateexportdifferentphysicochemicalpropertiesadditionallyassessedusingseveralfluorescentresultsshowlimitedimpacttransporterremarkablycontributesconsideredevaluatingviaFurthermorepromiscuitytakenaccountdevelopingnewantibioticExploringContributionHomologDrugResistanceDyeEffluxMultidrugResistantIsolateYhiV

Similar Articles

Cited By